Reference
Horowitz NS, et al. Compassionate use study of TRC105 (Endoglin Antibody) in combination with bevacizumab (Bev) in patients (pts) with refractory and metastatic choriocarcinoma. Journal of Clinical Oncology 34 (Suppl.): abstr. e17033, May 2016 [abstract] - United Kingdom
Rights and permissions
About this article
Cite this article
Bevacizumab/carotuximab. Reactions Weekly 1618, 41 (2016). https://doi.org/10.1007/s40278-016-21046-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-016-21046-1